Les Turner ALS Research Laboratories
Current Research Grants
Participate in Research Studies
Tissue Bank
Genetic Couseling
Clinical Trials

The Neuromuscular Disorders Program at Northwestern University Feinberg School of Medicine is actively involved in multi-center drug trials. They have participated in eleven ALS drug studies since 1993 and continue to pursue participation in new trials. Robert Sufit, M.D., Senda Ajroud-Driss, M.D. and Pat Casey, M.S., OTR/L, CCRC oversee the therapeutic clinical drug trials.

The Neuromuscular disorders Program is currently participating in a multi-center clinical research study sponsored by the National Institutes of Health (NIH) with Coenzyme Q10, a nutritional supplement, to evaluate its effect on maintaining functional abilities. Stage 1 has been completed; Stage 2 began in Spring 2007.

The center is looking forward to participation in the following prospective trials, which will be enrolling new patients once the trials have been initiated:
 
2006-2007 NeuroQOL (quality of life questionnaire study)
2007 Effects of excercise and nutrition of quality of life
2007 Coenzyme Q10 Stage 2
2007 Arimoclomol Phase II-III
2008-2009 Ceftriaxone
 

 
The center is currently involved in the following multi-center drug trials (these are closed to enrollment of new patients):
 
1998-2007  Xaliproden long-term study
 
The center has been involved with the following multi-center drug trials, only one of which as been approved by the FDA at this time:
 
1993-1994 CNTF (Ciliary neurotrophic factor) subcutaneous injection
1993-1995 Riluzole (Rilutek) oral medication
1995-1996 Riluzole early access program, prior to FDA approval
1994-1995 BDNF (Brain-derived neurotrophic factor) subcutaneous injection
1996 Riluzole FDA APPROVED
1995-1997 BDNF (Brain-derived neurotrophic factor) subcutaneous injection
1996-1998 Xaliproden oral medication
1998-2007 Xaliproden oral medication, long-term study
1998-2000 BDNF (Brain-derived neurotrophic factor) Intrathecal pump
2001-2002 Avanir - Neurodex submitted to FDA, oral medication for pseudobulbar affect
2003-2005 Novartis TCH346 oral medication
2004-2006 Coenzyme Q10 Stage 1 oral nutritional supplement
2005-2006 CYP1A2 and Riluzole

For more information, contact Pat Casey, M.S., OTR/L, CCRC, Clinical Research Coordinator at   pcasey1@nmff.org   or (312) 695-0774
   
  ClinicalTrials.gov
 
ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov provides information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals. Read More here.
 
Contact Us | Privacy Policy & Disclaimer | Site Map | Join Our Mailing List
   
  Les Turner ALS Foundation
5550 W. Touhy Avenue, Suite 302, Skokie, IL 60077-3254
847-679-3311 • 888-ALS-1107 (toll-free) • Fax: 847-679-9109